Bookmark
Forward
QuickView for lansoprazole (compound)
PubChem
| Name: | lansoprazole |
|---|---|
| PubChem Compound ID: | 3883 |
| Molecular formula: | C16H14F3N3O2S |
| Molecular weight: | 369.363 g/mol |
| Synonyms: |
DivK1c_000920; KBioSS_002060; 2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole; Ogast; Lanz; Spectrum_001580; D00355; Lanzopral; 1H-Benzimidazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-; AG 1749.
show more » |
DrugBank
Identification
| Name: | lansoprazole |
|---|---|
| Name (isomeric): | DB00448 |
| Drug Type: | small molecule |
| Synonyms: |
AG 1749
|
| Brand: | Opiren, Promp, Limpidex, Lanzol-30, Ogast, Lansoprazolum [INN-Latin], Agopton, Blason, Biuret Gr, Pro Ulco, Ogastro, Biuret Reagent, Lancid, Biuret, Aprazol, Prezal, Lansopep, Lanston, Takepron, Bamalite, Lanproton, Lanzopral, Lasoprol, Dakar, Zoprol, Ulpax, Lansoprazol [INN-Spanish], Prosogan, Mesactol, Zoton, Lanz, Prevpac, Amarin, Lanzor, Suprecid, Biuret Reagent Solution, Prevacid Iv, Ketian, Lansoprazole [Usan:Ban:Inn], Compraz, Prevacid Solutab, Monolitum, Ilsatec, Prevacid |
| Category: | Anti-Infective Agents, Anti-Ulcer Agents, Enzyme Inhibitors, Proton-pump Inhibitors, Anti-Infectives |
| CAS number: | 103577-45-3 |
Pharmacology
| Indication: | For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use. |
|---|---|
| Pharmacology: |
Lansoprazole, an acid proton-pump inhibitor similar to omeprazole, is used as an untiulcer drug in the treatment and maintenance of healing of duodenal or gastric ulcers, erosive and reflux esophagitis, NSAID-induced ulcer, Zollinger-Ellison syndrome, and Barrett's esophagus. Lansoprozole is active against Helicobacter pylori. The plasma eli...
show more » |
| Mechanism of Action: |
Lansoprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but rather suppress gastric acid secretion by specific inhibition of the (H+,K+)-ATPase enzyme system at the secretory surface of the gastric...
show more » |
| Absorption: | The absorption of lansoprazole is rapid, with mean Cmax occurring approximately 1.7 hours after oral dosing, and relatively complete with absolute bioavailability over 80%. |
| Protein binding: | 97% |
| Biotransformation: | Hepatic. Two metabolites have been identified in measurable quantities in plasma (the hydroxylated sulfinyl and sulfone derivatives of lansoprazole). These metabolites have very little or no antisecretory activity. Lansoprazole is thought to be transformed into two active species which inhibit acid secretion by (H+,K+)-ATPase within the parietal cell canaliculus, but are not present in the systemic circulation. |
| Route of elimination: | Following single-dose oral administration of PREVACID, virtually no unchanged lansoprazole was excreted in the urine. In one study, after a single oral dose of 14C-lansoprazole, approximately one-third of the administered radiation was excreted in the urine and two-thirds was recovered in the feces. This implies a significant biliary excretion of the lansoprazole metabolites. |
| Half Life: | 1.5 (± 1.0) hours |
| Toxicity: | Symptoms of overdose include abdominal pain, nausea and diarrhea. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
Transporters
